68 citations · 74 across the 7 of their papers we have counts for
7 papers
Uncertainty-Aware Multimodal Learning via Conformal Shapley Intervals
Mathew Chandy, Michael Johnson, Judong Shen +4
Multimodal learning combines information from multiple data modalities to improve predictive performance. However, modalities often contribute unequally and in a data dependent way…
Estimating heritability of survival traits using censored multiple variance component model
Do Hyun Kim, Hua Zhou, Brendon Chau +5
Characterizing the genetic basis of survival traits, such as age at disease onset, is critical for risk stratification, early intervention, and elucidating biological mechanisms th…
CAPITAL: Optimal Subgroup Identification via Constrained Policy Tree Search
Hengrui Cai, Wenbin Lu, Rachel Marceau West +2
Personalized medicine, a paradigm of medicine tailored to a patient's characteristics, is an increasingly attractive field in health care. An important goal of personalized medicin…
CauchyCP: a powerful test under non-proportional hazards using Cauchy combination of change-point Cox regressions
Hong Zhang, Qing Li, Devan V. Mehrotra +1
Non-proportional hazards data are routinely encountered in randomized clinical trials. In such cases, classic Cox proportional hazards model can suffer from severe power loss, with…
Principal Stratum Strategy: Potential Role in Drug Development
Björn Bornkamp, Kaspar Rufibach, Jianchang Lin +6
A randomized trial allows estimation of the causal effect of an intervention compared to a control in the overall population and in subpopulations defined by baseline characteristi…
Survival Analysis Using a 5-Step Stratified Testing and Amalgamation Routine in Randomized Clinical Trials
Devan V. Mehrotra, Rachel Marceau West
Randomized clinical trials are often designed to assess whether a test treatment prolongs survival relative to a control treatment. Increased patient heterogeneity, while desirable…
PRISM: Patient Response Identifiers for Stratified Medicine
Thomas O. Jemielita, Devan V. Mehrotra
Pharmaceutical companies continue to seek innovative ways to explore whether a drug under development is likely to be suitable for all or only an identifiable stratum of patients i…